Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DSP 0390

Next Previous
Drug Profile

DSP 0390

Alternative Names: DSP-0390; TP-0390

Latest Information Update: 29 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sumitomo Dainippon Pharma; Tolero Pharmaceuticals
  • Developer Sumitomo Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action EBP protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma
  • No development reported Solid tumours

Most Recent Events

  • 29 Apr 2025 DSP 0390 is still in phase I trials for Glioma (Recurrent) in USA, Japan (PO) (Sumitomo Pharma pipeline, April 2025)
  • 10 Oct 2024 Washington University School of Medicine in collaboration with Sumitomo Pharmaceuticals America plans an early phase I trial for Glioma (Recurrent) in USA (PO) (NCT06636162)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Solid-tumours in Japan (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top